<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558830</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-0121</org_study_id>
    <nct_id>NCT01558830</nct_id>
  </id_info>
  <brief_title>Safety of Amiodarone and Ranolazine Together in Patients With Angina</brief_title>
  <acronym>SARA</acronym>
  <official_title>Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Consultants of Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiovascular Consultants of Nevada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ranolazine is an effective and remarkably safe agent for the treatment of patients with
      chronic stable angina, but its inhibition of voltage gated potassium channels and
      electrocardiogram (EKG) corrected QT (QTc) prolongation properties have lead many to question
      its safety when combined with antiarrhythmic drugs. The investigators have proposed a study
      to determine the safety of ranolazine in patients with chronic stable angina who also take
      amiodarone. And are conducting a prospective single-center randomized single-blinded placebo
      controlled trial to run out of our large cardiology practice setting at Cardiovascular
      Consultants of Nevada. The hypothesis is that there will be no difference in the ventricular
      arrhythmia burden. The primary outcome will be the measurement of ventricular arrhythmia
      episodes on serial holter monitor and other serially acquired recordings (such as
      electrocardiogram, pacemaker or implantable defibrillator (ICD) data, and stress test data)
      over a three month trial period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventricular arrhythmia</measure>
    <time_frame>3 months</time_frame>
    <description>primary outcome is the burden of ventricular arrhythmias measured on serial holter monitor recordings, stress test recordings, pacemaker or implantable defibrillator (ICD) recordings if available, at baseline and serially to trial completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>atrial arrhythmia burden</measure>
    <time_frame>3 months</time_frame>
    <description>burden of atrial arrhythmias will be measured on serial holter monitor recordings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (EKG) corrected QT (QTc) interval measurement</measure>
    <time_frame>over the 3 month trial</time_frame>
    <description>The electrocardiogram (EKG) corrected QT (QTc) interval be quantitated at baseline and serially to trial completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Hospitalization rates, if any, will be serially quantitated to trial completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>syncope hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>syncope hospitalization rate quantitation to trial completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function assay</measure>
    <time_frame>3 months</time_frame>
    <description>serum liver function testing will be conducted at baseline and serially to trial completion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Stable Angina</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranolazine</intervention_name>
    <description>ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ischemic cardiac disease

          -  chronic anginal symptoms

          -  on amiodarone therapy for other cardiac conditions

        Exclusion Criteria:

          -  pregnant

          -  non-English speaking

          -  unstable angina

          -  baseline electrocardiogram (EKG) corrected QT (QTc)&gt;490ms

          -  severe thyroid dysfunction

          -  heart block without a pacer system

          -  liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik J SIrulnick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Consultants of Nevada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik J Sirulnick, MD</last_name>
    <phone>702-731-8224</phone>
    <email>erikmd@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christie Abano, RN</last_name>
    <phone>702-731-8224</phone>
    <email>cabano@ccnv.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Consultants of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89196</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amiodarone</keyword>
  <keyword>ranolazine</keyword>
  <keyword>safety</keyword>
  <keyword>arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 6, 2015</submitted>
    <returned>May 21, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

